TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21394500

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 4 mg administered intravenously after each chemotherapy cycle for 60 months post-randomisation (six doses in the first 6 months, eight doses in the following 24 months and five doses in the final 30 months).
Number of subjects: 3340

Group type: COMPARATOR
Intervention: Control group received neither additional treatment nor intravenous ZOL.
Number of subjects: 3340
Study: 19013924

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training methods (specifically 'The Knack' and 'The Perineal Lock')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (general)
Number of subjects: 0
Study: 16627862

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (nonrebreather bag-valve mask)
Number of subjects: 53
Study: 14994569

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (Group A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No nitric oxide inhalation (Group B)
Number of subjects: 14
Study: 10978060

Group type: EXPERIMENTAL
Intervention: Hypothermic treatment using the 'forced air' method for 6 hours (cooling blanket with a flow of cool air at 10 degrees C)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hypothermic treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (56 patients matched for age, gender, initial stroke severity, body temperature on admission, and time from stroke onset to admission)
Number of subjects: 17
Study: 8869682

Group type: EXPERIMENTAL
Intervention: Detergent (sodium lauryl sulphate) at 40 degrees C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Detergent (sodium lauryl sulphate) at 20 degrees C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 20
Study: 1739570

Group type: EXPERIMENTAL
Intervention: Propofol at doses of 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, and 2.6 mg kg‐1
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 300
Study: 6377784

Group type: EXPERIMENTAL
Intervention: metronidazole/fosfomycin
Number of subjects: 49

Group type: COMPARATOR
Intervention: metronidazole/placebo
Number of subjects: 49
Study: 28921778

Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention 'Alcohol e-Health'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 27472252

Group type: EXPERIMENTAL
Intervention: Internal Jugular Vein
Number of subjects: 280

Group type: COMPARATOR
Intervention: Subclavian Vein
Number of subjects: 280
Study: 25666112

Group type: EXPERIMENTAL
Intervention: Protective soccer headband
Number of subjects: 25

Group type: COMPARATOR
Intervention: No headband
Number of subjects: 25
Study: 23360359

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) 200 mg/d for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21397383

Group type: EXPERIMENTAL
Intervention: Target Volume Marked Bag (TVMB)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Adult Bag
Number of subjects: 53

Group type: COMPARATOR
Intervention: Paediatric Bag
Number of subjects: 53
Study: 18433304

Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/d)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 16540798

Group type: EXPERIMENTAL
Intervention: Higher-LCPUFA formula with 17 mg DHA, 34 mg ARA, 85 mg ALA, and 860 mg LA per 100 kcal
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lower-LCPUFA formula with 8 mg DHA, 21 mg ARA, 110 mg ALA, and 1,000 mg LA per 100 kcal
Number of subjects: 78
Study: 14575766

Group type: EXPERIMENTAL
Intervention: GM-CSF (20 microg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study: 10885162

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 225
Study: 8829094

Group type: EXPERIMENTAL
Intervention: Formula and cereal
Number of subjects: 41

Group type: COMPARATOR
Intervention: Formula alone
Number of subjects: 41
Study: 1591828

Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator (100 mg over 2 hours)
Number of subjects: 197

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: angioplasty
Number of subjects: 197

Group type: COMPARATOR
Intervention: no angioplasty
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator
Number of subjects: 197
Study: 3901674

Group type: EXPERIMENTAL
Intervention: Routine care plus monitoring by a specialist nurse
Number of subjects: 152

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Antidepressant medication plus cognitive therapy
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cognitive therapy alone
Number of subjects: 152
Study: 30453332

Group type: EXPERIMENTAL
Intervention: Short-term intensive (STI) therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 11
Study: 30646152

Group type: EXPERIMENTAL
Intervention: Shared financial incentives for patients and physicians
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Trial control strategy (increased cholesterol level monitoring and use of electronic pill bottles)
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Financial incentives for physicians
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Financial incentives for patients
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000000
Study: 26745211

Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy and family-based behavioral treatment (mean duration 70.04 days)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy and family-based behavioral treatment
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy and behavioral treatment
Number of subjects: 156
Study: 24934962

Group type: EXPERIMENTAL
Intervention: Varenicline plus bupropion
Number of subjects: 222

Group type: COMPARATOR
Intervention: Varenicline plus placebo
Number of subjects: 222
Study: 22129562

Group type: EXPERIMENTAL
Intervention: Antidepressant medication combinations (mirtazapine and venlafaxine)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 665
Study: 20012484

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg twice daily
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 18843432

Group type: EXPERIMENTAL
Intervention: Resistance training combined with coenzyme Q10 supplementation (200 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16640511

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15022975

Group type: EXPERIMENTAL
Intervention: Therapeutic group by telephone conference call
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual psychosocial care
Number of subjects: 66
Study: 11192705

Group type: EXPERIMENTAL
Intervention: Dobutamine plus low-level exercise (Group B)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Dobutamine alone (Group A)
Number of subjects: 58
Study: 8630467

Group type: EXPERIMENTAL
Intervention: Bradykinin levels in BAL fluid in patients with sarcoidosis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls (9 participants)
Number of subjects: 14
Study: 1705386

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/day
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Sotalol 640 mg/day
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 6366344

Group type: EXPERIMENTAL
Intervention: Efemoline eyedrops (fluorometholone 0.1% + tetryzoline 0.25%)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 35
Study: 31540611

Group type: EXPERIMENTAL
Intervention: Illicit opioid use
Number of subjects: 37

Group type: COMPARATOR
Intervention: Early clinic hours (07:00-09:00)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Late clinic hours (12:00-13:00)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard clinic hours (07:00-11:30)
Number of subjects: 37
Study: 29316996

Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 26872008

Group type: EXPERIMENTAL
Intervention: Irinotecan 125 mg/m2 and cisplatin 60 mg/m2 (high-dose group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Irinotecan 80 mg/m2 and cisplatin 50 mg/m2 (low-dose group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both high-dose and low-dose groups
Number of subjects: 41
Study: 23338668

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 4 % spray gel applied two or three times daily for 3 days
Number of subjects: 39
Study: 21831478

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscopy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Flexible fiber-optic laryngoscopy
Number of subjects: 23
Study: 20078213

Group type: EXPERIMENTAL
Intervention: DNA/rAd5 vaccination regimen
Number of subjects: 324

Group type: COMPARATOR
Intervention: rAd5 alone
Number of subjects: 324
Study: 17324628

Group type: EXPERIMENTAL
Intervention: 10 g of carbohydrates per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: 20 g of carbohydrates per day
Number of subjects: 20
Study: 16132885

Group type: EXPERIMENTAL
Intervention: TPN with glucose/lipid ratio of 50/50
Number of subjects: 47

Group type: COMPARATOR
Intervention: TPN with glucose/lipid ratio of 80/20
Number of subjects: 47
Study: 12137830

Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation (TUNA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham treatment (urethrocystoscopy)
Number of subjects: 33
Study: 10448776

Group type: EXPERIMENTAL
Intervention: Haloperidol, thioridazine, and lorazepam
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 8578801

Group type: EXPERIMENTAL
Intervention: SPf(66)n synthetic malaria vaccine
Number of subjects: 0
Study: 2112167

Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 106
Study: 526404

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 19

Group type: COMPARATOR
Intervention: methyldopa
Number of subjects: 19
Study: 31164156

Group type: EXPERIMENTAL
Intervention: Age group 20-24 years
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Age group 25-29 years
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Age group 30-34 years
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Educational level primary
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Educational level secondary
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Educational level college diploma and above
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Monthly income 1001-2000 Ethiopian birr
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Monthly income 2001-3000 Ethiopian birr
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Years in marriage 1-2 years
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Last time of abortion 1-2 years
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Last time of abortion 2-3 years
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Last time of abortion above 3 years
Number of subjects: 429
Study: 28223265

Group type: EXPERIMENTAL
Intervention: AI platform (AiCure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mDOT
Number of subjects: 0
Study: 25561337

Group type: EXPERIMENTAL
Intervention: Isavuconazole 200 mg on day 1 and then 50 mg once daily (arm A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Isavuconazole 400 mg on day 1 and then 400 mg once-weekly (arm B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Isavuconazole 400 mg on day 1 and then 100 mg once daily (arm C)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Fluconazole 200 mg on day 1 and then 100 mg once daily (arm D)
Number of subjects: 160
Study: 23324133

Group type: EXPERIMENTAL
Intervention: 12 weeks of medical care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Concurrent medical and chiropractic care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Collaborative medical and chiropractic care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 21876476

Group type: EXPERIMENTAL
Intervention: cinacalcet (30 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control phase without cinacalcet
Number of subjects: 10
Study: 19706990

Group type: EXPERIMENTAL
Intervention: Exenatide QW 0.8 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exenatide QW 2.0 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo QW
Number of subjects: 30
Study: 17885315

Group type: EXPERIMENTAL
Intervention: Early rehabilitation program starting within the second week after operation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Late rehabilitation program starting within the fourth week after operation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both early and late rehabilitation programs
Number of subjects: 300
Study: 15587227

Group type: COMPARATOR
Intervention: Selective Reminding Test (Buschke 12‐word, six‐trial)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Performance on alternate forms of the Selective Reminding Test
Number of subjects: 75

Group type: COMPARATOR
Intervention: Mean education, intelligence quotient, and Wide Range Achievement Test‐3 Reading scores
Number of subjects: 75
Study: 11522174

Group type: EXPERIMENTAL
Intervention: Lactation education and palatal obturation (C1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lactation education and palatal obturation (C2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Haberman bottle feeding (B1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Haberman bottle feeding (B2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lactation education and palatal obturation
Number of subjects: 8
Study: 9756250

Group type: EXPERIMENTAL
Intervention: 20 g hydrolyzed guar fiber
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7923804

Group type: EXPERIMENTAL
Intervention: Alpha-interferon (Alfaferone: Alfa-Wassermann Bologna, Italy) 3 x 10(6) IU by i.m. injection every other day for four weeks (total of 12 injections)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3288812

Group type: EXPERIMENTAL
Intervention: Surgery with postoperative radiation (n = 24)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Surgery alone (n = 27)
Number of subjects: 51
Study: 31557450

Group type: EXPERIMENTAL
Intervention: DXM+ (Dexmedetomidine infusion at 4 μg/kg/hr)
Number of subjects: 12

Group type: COMPARATOR
Intervention: DXM- (Control sedation with midazolam, fentanyl, and propofol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DXM+
Number of subjects: 12
Study: 31264017

Group type: EXPERIMENTAL
Intervention: Deep learning with convolutional neural networks (CNN) using midsagittal T1-weighted MRI
Number of subjects: 419
Study: 28800383

Group type: EXPERIMENTAL
Intervention: GSK2793660 (12 mg once daily for 21 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GSK2793660 (single escalating doses from 0.5 to 20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25747157

Group type: EXPERIMENTAL
Intervention: Active acupuncture with a penetrating needle
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo acupuncture with a non-penetrating needle
Number of subjects: 67
Study: 23364629

Group type: EXPERIMENTAL
Intervention: Oral paricalcitol treatment at doses of 1 mcg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1 ampoule calcifediol/wk (0.266 mg/wk=16 000U) orally
Number of subjects: 26
Study: 21636158

Group type: EXPERIMENTAL
Intervention: Carbohydrate counting sliding scale (CSc)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard sliding scale (Sc)
Number of subjects: 64
Study: 19490137

Group type: EXPERIMENTAL
Intervention: Group II: verbal instructions and a self-educational manual on oral hygiene without illustrations
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Group III: oral hygiene guidance with verbal instructions and a self-teaching manual
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control Group I: continued personal oral hygiene routine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 53
Study: 17046166

Group type: EXPERIMENTAL
Intervention: 300 mg oral micronized progesterone
Number of subjects: 52
Study: 15301325

Group type: EXPERIMENTAL
Intervention: Intensive glucose management protocol (continuous intravenous insulin if glucose >200 mg/dL, target glucose <140 mg/dL)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Intensive glucose management protocol
Number of subjects: 1600
Study: 11706484

Group type: EXPERIMENTAL
Intervention: Motor Relearning Programme (MRP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bobath method
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (MRP and Bobath)
Number of subjects: 61
Study: 9152646

Group type: EXPERIMENTAL
Intervention: Troponin T < 0.06 (n = 154)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Troponin T 0.06-0.2 (n = 175)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Troponin T >= 0.2 (n = 437)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Low risk exercise test response (n = 361)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Intermediate risk exercise test response (n = 325)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: High risk exercise test response (n = 80)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Combination of troponin T and exercise test response (Low risk n = 84)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Combination of troponin T and exercise test response (Intermediate risk n = 406)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Combination of troponin T and exercise test response (High risk n = 276)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Troponin T < 0.06 in patients unable to perform exercise test (n = 197)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Troponin T 0.06-0.2 in patients unable to perform exercise test (n = 197)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Troponin T >= 0.2 in patients unable to perform exercise test (n = 197)
Number of subjects: 963
Study: 8490912

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg plus clindamycin 600 mg every 8 hours
Number of subjects: 83

Group type: COMPARATOR
Intervention: IV aztreonam 2 g plus clindamycin 600 mg every 8 hours
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oral regimen
Number of subjects: 83

Group type: COMPARATOR
Intervention: IV regimen
Number of subjects: 83
Study: 3124734

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g intravenously every 12 hours
Number of subjects: 28
Study: 31542816

Group type: EXPERIMENTAL
Intervention: Flexible reamers
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rigid reamers
Number of subjects: 50
Study: 29611275

Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (ADT)
Number of subjects: 597
Study: 27316224

Group type: EXPERIMENTAL
Intervention: Intranasal sodium citrate solution
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sodium chloride solution (placebo control)
Number of subjects: 57
Study: 25195371

Group type: EXPERIMENTAL
Intervention: High dose Qianlongtong Capsule (6 capsules once, tid for 7 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Medium dose Qianlongtong Capsule (3 capsules once, tid for 7 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low dose Qianlongtong Capsule (1.5 capsules once, tid for 7 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Blank control group (no QLT)
Number of subjects: 15
Study: 22422075

Group type: EXPERIMENTAL
Intervention: 1-year mortality predictive index
Number of subjects: 7373

Group type: EXPERIMENTAL
Intervention: 5-year mortality predictive index
Number of subjects: 7373

Group type: EXPERIMENTAL
Intervention: 10-year mortality predictive index
Number of subjects: 7373
Study: 20872114

Group type: EXPERIMENTAL
Intervention: Chinese medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 0
Study: 18592210

Group type: EXPERIMENTAL
Intervention: Early tracheotomy (ET) within 4 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: Prolonged intubation (PI)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Early tracheotomy (ET)
Number of subjects: 123
Study: 15801915

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg continuous treatment (once daily)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg on-demand treatment
Number of subjects: 176

Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Overall quality of life score
Number of subjects: 176
Study: 12451189

Group type: COMPARATOR
Intervention: IFNbeta‐1a 30 micro g IM once weekly
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 60 micro g IM once weekly
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: MRI measure at month 36
Number of subjects: 802
Study: 11019837

Group type: EXPERIMENTAL
Intervention: lenograstim-mobilized PBSCT
Number of subjects: 39

Group type: COMPARATOR
Intervention: BMT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: <2 x 10(6) CD34+ cells/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: >=2 x 10(6) CD34+ cells/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CD34+ cell dose >=2 x 10(6)/kg
Number of subjects: 39
Study: 9260226

Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS) solution for 15 sec, rinsed, and covered by zinc oxide‐eugenol paste (ZOE)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dilute formocresol (DFC) with a cotton pellet moistened with 20% for 5 min, removed, and pulp stumps covered by ZOE paste
Number of subjects: 72
Study: 1441366

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thymalin (immunomodulators)
Number of subjects: 50